Psychedelic-Assisted Therapy: An Overview for Nonpsychiatrists

Psychedelic-assisted therapy combines psychotherapy with psychedelics like MDMA and psilocybin, aiming to treat depression, PTSD, and substance use disorders. Early clinical evidence suggests these approaches may be effective, though the field remains experimental. The overview explains how psychedelic-assisted therapy is delivered in trials: preparation sessions to build therapeutic alliance and set intentions, supervised sessions in a designed treatment space (often with music, eyeshades, and monitoring), and follow-up integration sessions to turn insights into durable behavior change. Sessions can last around 6 to 8 hours, and patients typically have medical evaluation and discharge instructions after dosing. It also addresses provider readiness for possible future FDA approvals, highlighting that internists and other clinicians may need guidance on safety in real-world populations, including older patients and those excluded from trials. The article notes FDA breakthrough designations for MDMA and psilocybin, while also describing regulatory setbacks and the need to learn how to optimize protocols in clinical practice.